<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820586</url>
  </required_header>
  <id_info>
    <org_study_id>TVICPR-003</org_study_id>
    <nct_id>NCT00820586</nct_id>
  </id_info>
  <brief_title>Intramyocardial Delivery of Autologous Bone Marrow</brief_title>
  <official_title>Intramyocardial Delivery of Autologous Bone Marrow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized study to assess the safety, feasibility and effectiveness of direct
      intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear
      cells or selected CD34+ cells in patients with refractory angina pectoris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoint: Incidence of major adverse cardiac events (MACE) at 30 days. MACE is
      defined as a combined endpoint of death, acute MI (Q-wave and non-Q wave), revascularization
      procedures (percutaneous or surgical), and peri-procedural complications (that is, left
      ventricular perforation with hemodynamic consequences requiring pericardiocentesis, and
      stroke).

      Incidence of MACE at 3, 6 and 12 months

      Secondary Endpoints:

        -  Change in Canadian Cardiovascular Society (CCS) angina classification score from
           baseline to 12 months

        -  Changes in the quality of life, as assessed according to the Seattle Angina
           Questionnaire

        -  Change in exercise duration and exercise tolerance using standardized treadmill exercise
           testing from baseline, to 6 months and to 12 months

        -  Cumulative number of hospitalizations for coronary ischemia and congestive heart failure
           at 12 months following treatment.

        -  SPECT-chances in global and regional radionuclide perfusion at rest, peak stress, and
           redistribution for baseline to 1, 6 and 12 months

        -  Change in angiographic collateral score at 6 months

        -  Change in global and regional myocardial contractility (assessed by echocardiography) at
           baseline, 6 and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    No more funding support for additional procedures
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of major adverse cardiac events (MACE), defined as a combined endpoint of death, acute MI (Q-wave and non-Q wave), revascularization procedures and peri-procedural complications.</measure>
    <time_frame>1, 6, 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Canadian Cardiovascular Society (CCS) angina classification score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the quality of life, as assessed according to the Seattle Angina Questionnaire</measure>
    <time_frame>1,3,6,12 months and every year for 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exercise duration and exercise tolerance using standardized treadmill exercise testing</measure>
    <time_frame>6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of hospitalizations for coronary ischemia and congestive heart failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPECT-chances in global and regional radionuclide perfusion at rest, peak stress, and redistribution</measure>
    <time_frame>1, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in angiographic collateral score</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in global and regional myocardial contractility (assessed by echocardiography)</measure>
    <time_frame>6, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Refractory Angina</condition>
  <arm_group>
    <arm_group_label>Mononuclear bone marrow derived cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramyocardial injection of total mononuclear bone marrow derived cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selected CD34+ bone marrow derived cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramyocardial injection of selected CD34+ bone marrow derived cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mononuclear bone marrow derived cells</intervention_name>
    <description>Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells</description>
    <arm_group_label>Mononuclear bone marrow derived cells</arm_group_label>
    <arm_group_label>Selected CD34+ bone marrow derived cells</arm_group_label>
    <other_name>Selected CD34+ bone marrow derived cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Subjects &gt;21 years old;

          2. Subjects with functional class (CCS) III or IV angina;

          3. Subjects with left ventricular (LV) ejection fraction ³ 30%

          4. Attempted &quot;best&quot; tolerated medical therapy

          5. Clinical signs and symptoms of myocardial ischemia with reversible ischemia on
             perfusion imaging;

          6. Patient deemed to be a poor candidate or at high surgical risk;

          7. Subject must be able to complete a minimum of 2 minutes but no more than 10 minutes
             exercise test (Bruce Protocol);

          8. Subject (or their legal guardian) understands the nature of the procedure and provides
             written consent prior to the procedure;

          9. Subject is willing to comply with specified follow-up evaluations;

         10. Patient must develop angina and a horizontal or down-sloping ST-segment depression of
             ³ 1 mm during exercise, compared to pre-exercise ST segment, 80 ms from the J point or
             moderate angina with or without the above ST segment changes.

        Angiographic Inclusion Criteria:

          1. Severe obstruction (lumen diameter stenosis &gt; 70%) in a coronary or surgical conduit
             felt to be solely or partially responsible for angina and myocardial ischemia;

          2. There must be at least one coronary or surgical conduit with &lt; 70% diameter stenosis

          3. Poor candidate for percutaneous coronary intervention of treatment zone

          4. Poor candidates for surgical revascularization procedures, such as inadequate target
             coronary anatomy or lack of potential surgical conduits.

        Exclusion Criteria:

          1. Pregnant women;

          2. Left ventricular ejection fraction &lt;30% as assessed by either echocardiography or left
             ventriculography;

          3. Severe cardiac heart failure with NYHA functional class III-IV symptoms;

          4. Chronic atrial fibrillation;

          5. Prosthetic aortic valve;

          6. Severe (grade III-IV) mitral or aortic insufficiency;

          7. Wall thickness of &lt;8 mm (defined by echocardiography) of the proposed target region of
             myocardium;

          8. Severe co-morbidity associated with a reduction in life expectancy of &lt;1 year, such as
             chronic medical illnesses

          9. Braunwald class II unstable angina

         10. Severe peripheral (or aortic) vascular disease which might increase the risk of
             vascular complications (perforation, dissection or embolization);

         11. Significant aortic valve pathologic sclerosis or stenosis

         12. LV thrombus (mobile or mural-based) seen on echocardiography;

         13. Recent (within 4 weeks) documented myocardial infarction (Q and/or non-Q wave) defined
             as CK-MB &gt;3times upper normal level;

         14. Currently enrolled in another investigational device or drug trial that has not
             completed the required follow-up period;

         15. Thrombocytopenia or history of heparin-induced thrombocytopenia or thrombocytosis

         16. Leukopenia

         17. Leukocytosis

         18. Anemia or erythrocytosis

         19. Active peptic ulcer or active gastrointestinal bleeding;

         20. Chronic renal failure requiring dialysis;

         21. Prior or current malignancy

         22. Other conditions that can significantly affect the bone-marrow

         23. Evidence of concurrent infection (WBC &gt;12.000 mm3, temperature &gt;38.5° C);

         24. Serological of clinical evidence of HIV

         25. Immunotherapy

         26. Abnormal bone-marrow morphology as evident in bone-marrow smear prior to the
             intervention

        Angiographic/Ventriculographic Exclusion Criteria:

          1. LV thrombus (mobile or mural-based) seen on left ventriculography;

          2. Coronary lesions suitable for percutaneous coronary interventions;

          3. Unprotected left main coronary artery disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS S. Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Losordo DW, Vale PR, Isner JM. Gene therapy for myocardial angiogenesis. Am Heart J. 1999 Aug;138(2 Pt 2):S132-41. Review.</citation>
    <PMID>10426872</PMID>
  </reference>
  <reference>
    <citation>Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE, Rosengart TK. Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation. 2000 Sep 12;102(11):E73-86. Review.</citation>
    <PMID>10982554</PMID>
  </reference>
  <reference>
    <citation>Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science. 1990 Sep 14;249(4974):1285-8.</citation>
    <PMID>2119055</PMID>
  </reference>
  <reference>
    <citation>Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation. 1998 Feb 24;97(7):645-50.</citation>
    <PMID>9495299</PMID>
  </reference>
  <reference>
    <citation>Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996 Aug 10;348(9024):370-4.</citation>
    <PMID>8709735</PMID>
  </reference>
  <reference>
    <citation>Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999 Aug 3;100(5):468-74.</citation>
    <PMID>10430759</PMID>
  </reference>
  <reference>
    <citation>Vale PR, Losordo DW, Milliken CE, McDonald MC, Gravelin LM, Curry CM, Esakof DD, Maysky M, Symes JF, Isner JM. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation. 2001 May 1;103(17):2138-43.</citation>
    <PMID>11331253</PMID>
  </reference>
  <reference>
    <citation>Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999 Aug 6;85(3):221-8.</citation>
    <PMID>10436164</PMID>
  </reference>
  <reference>
    <citation>Kobayashi T, Hamano K, Li TS, Katoh T, Kobayashi S, Matsuzaki M, Esato K. Enhancement of angiogenesis by the implantation of self bone marrow cells in a rat ischemic heart model. J Surg Res. 2000 Apr;89(2):189-95.</citation>
    <PMID>10729249</PMID>
  </reference>
  <reference>
    <citation>Tomita S, Mickle DA, Weisel RD, Jia ZQ, Tumiati LC, Allidina Y, Liu P, Li RK. Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg. 2002 Jun;123(6):1132-40.</citation>
    <PMID>12063460</PMID>
  </reference>
  <reference>
    <citation>Shintani S, Murohara T, Ikeda H, Ueno T, Sasaki K, Duan J, Imaizumi T. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation. 2001 Feb 13;103(6):897-903.</citation>
    <PMID>11171801</PMID>
  </reference>
  <reference>
    <citation>Fuchs S, Baffour R, Zhou YF, Shou M, Pierre A, Tio FO, Weissman NJ, Leon MB, Epstein SE, Kornowski R. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol. 2001 May;37(6):1726-32.</citation>
    <PMID>11345391</PMID>
  </reference>
  <reference>
    <citation>Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003 Jan 4;361(9351):47-9.</citation>
    <PMID>12517468</PMID>
  </reference>
  <reference>
    <citation>Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001 Apr 5;410(6829):701-5.</citation>
    <PMID>11287958</PMID>
  </reference>
  <reference>
    <citation>Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Amano K, Iba O, Imada T, Iwasaka T. Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1804-10. Erratum in: Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):212.</citation>
    <PMID>12426208</PMID>
  </reference>
  <reference>
    <citation>Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C, Uchida S, Masuo O, Iwaguro H, Ma H, Hanley A, Silver M, Kearney M, Losordo DW, Isner JM, Asahara T. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation. 2003 Jan 28;107(3):461-8.</citation>
    <PMID>12551872</PMID>
  </reference>
  <reference>
    <citation>Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002 Aug 10;360(9331):427-35.</citation>
    <PMID>12241713</PMID>
  </reference>
  <reference>
    <citation>Assmus B, Schächinger V, Teupe C, Britten M, Lehmann R, Döbert N, Grünwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002 Dec 10;106(24):3009-17.</citation>
    <PMID>12473544</PMID>
  </reference>
  <reference>
    <citation>Strauer BE, Brehm M, Zeus T, Köstering M, Hernandez A, Sorg RV, Kögler G, Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002 Oct 8;106(15):1913-8.</citation>
    <PMID>12370212</PMID>
  </reference>
  <reference>
    <citation>Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, Rossi MI, Carvalho AC, Dutra HS, Dohmann HJ, Silva GV, Belém L, Vivacqua R, Rangel FO, Esporcatte R, Geng YJ, Vaughn WK, Assad JA, Mesquita ET, Willerson JT. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003 May 13;107(18):2294-302. Epub 2003 Apr 21.</citation>
    <PMID>12707230</PMID>
  </reference>
  <reference>
    <citation>Fuchs S, Satler LF, Kornowski R, Okubagzi P, Weisz G, Baffour R, Waksman R, Weissman NJ, Cerqueira M, Leon MB, Epstein SE. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J Am Coll Cardiol. 2003 May 21;41(10):1721-4.</citation>
    <PMID>12767654</PMID>
  </reference>
  <reference>
    <citation>Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006 Dec;27(23):2775-83. Epub 2006 Nov 10.</citation>
    <PMID>17098754</PMID>
  </reference>
  <reference>
    <citation>Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grøgaard HK, Bjørnerheim R, Brekke M, Müller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1199-209.</citation>
    <PMID>16990383</PMID>
  </reference>
  <reference>
    <citation>Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006 Mar 14;113(10):1287-94. Epub 2006 Mar 6.</citation>
    <PMID>16520413</PMID>
  </reference>
  <reference>
    <citation>Kim MC, Kini A, Sharma SK. Refractory angina pectoris: mechanism and therapeutic options. J Am Coll Cardiol. 2002 Mar 20;39(6):923-34. Review.</citation>
    <PMID>11897431</PMID>
  </reference>
  <reference>
    <citation>Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, Follath F, Hellemans I, Herlitz J, Lüscher T, Pasic M, Thelle D. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J. 2002 Mar;23(5):355-70. Review.</citation>
    <PMID>11846493</PMID>
  </reference>
  <reference>
    <citation>Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG. Direct myocardial revascularization and angiogenesis--how many patients might be eligible? Am J Cardiol. 1999 Sep 1;84(5):598-600, A8.</citation>
    <PMID>10482164</PMID>
  </reference>
  <reference>
    <citation>Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, Fihn SD. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995 Feb;25(2):333-41.</citation>
    <PMID>7829785</PMID>
  </reference>
  <reference>
    <citation>Vale PR, Losordo DW, Tkebuchava T, Chen D, Milliken CE, Isner JM. Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping. J Am Coll Cardiol. 1999 Jul;34(1):246-54.</citation>
    <PMID>10400018</PMID>
  </reference>
  <reference>
    <citation>Ben-Haim SA, Osadchy D, Schuster I, Gepstein L, Hayam G, Josephson ME. Nonfluoroscopic, in vivo navigation and mapping technology. Nat Med. 1996 Dec;2(12):1393-5.</citation>
    <PMID>8946843</PMID>
  </reference>
  <reference>
    <citation>Kornowski R, Hong MK, Gepstein L, Goldstein S, Ellahham S, Ben-Haim SA, Leon MB. Preliminary animal and clinical experiences using an electromechanical endocardial mapping procedure to distinguish infarcted from healthy myocardium. Circulation. 1998 Sep 15;98(11):1116-24.</citation>
    <PMID>9736599</PMID>
  </reference>
  <reference>
    <citation>Gepstein L, Goldin A, Lessick J, Hayam G, Shpun S, Schwartz Y, Hakim G, Shofty R, Turgeman A, Kirshenbaum D, Ben-Haim SA. Electromechanical characterization of chronic myocardial infarction in the canine coronary occlusion model. Circulation. 1998 Nov 10;98(19):2055-64.</citation>
    <PMID>9808605</PMID>
  </reference>
  <reference>
    <citation>Kornowski R, Hong MK, Leon MB. Comparison between left ventricular electromechanical mapping and radionuclide perfusion imaging for detection of myocardial viability. Circulation. 1998 Nov 3;98(18):1837-41.</citation>
    <PMID>9799201</PMID>
  </reference>
  <reference>
    <citation>Hamano K, Nishida M, Hirata K, Mikamo A, Li TS, Harada M, Miura T, Matsuzaki M, Esato K. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. Jpn Circ J. 2001 Sep;65(9):845-7.</citation>
    <PMID>11548889</PMID>
  </reference>
  <results_reference>
    <citation>Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1222-32.</citation>
    <PMID>16990385</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>February 1, 2012</last_update_submitted>
  <last_update_submitted_qc>February 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Antonio Colombo</investigator_full_name>
    <investigator_title>Director of Invasive Cardiology Unit</investigator_title>
  </responsible_party>
  <keyword>Intramyocardial</keyword>
  <keyword>Autologous</keyword>
  <keyword>Bone</keyword>
  <keyword>Marrow</keyword>
  <keyword>Randomized</keyword>
  <keyword>Percutaneous</keyword>
  <keyword>CD34+</keyword>
  <keyword>Refractory</keyword>
  <keyword>Angina</keyword>
  <keyword>Pectoris.</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

